WO2007026219A3 - Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions - Google Patents

Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions Download PDF

Info

Publication number
WO2007026219A3
WO2007026219A3 PCT/IB2006/002364 IB2006002364W WO2007026219A3 WO 2007026219 A3 WO2007026219 A3 WO 2007026219A3 IB 2006002364 W IB2006002364 W IB 2006002364W WO 2007026219 A3 WO2007026219 A3 WO 2007026219A3
Authority
WO
WIPO (PCT)
Prior art keywords
noradrenalin
inhibitor
serotonin
reutake
combinations
Prior art date
Application number
PCT/IB2006/002364
Other languages
French (fr)
Other versions
WO2007026219A2 (en
Inventor
Wilma Marcia Harrison
Susan Beth Sobolov-Jaynes
Robert Sterling Foerster Jr
Beek Jeroen Bernard Van
Original Assignee
Pfizer Prod Inc
Wilma Marcia Harrison
Susan Beth Sobolov-Jaynes
Robert Sterling Foerster Jr
Beek Jeroen Bernard Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Wilma Marcia Harrison, Susan Beth Sobolov-Jaynes, Robert Sterling Foerster Jr, Beek Jeroen Bernard Van filed Critical Pfizer Prod Inc
Publication of WO2007026219A2 publication Critical patent/WO2007026219A2/en
Publication of WO2007026219A3 publication Critical patent/WO2007026219A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising 5-HT1B antagonists in combination with noradrenaline re-uptake inhibitor (NRI) or serotonin noradrenaline reuptake inhibitor (SNRI) and optionally a pharmaceutically acceptable carrier, and to their medicinal use in treating or preventing CNS conditions such as depression, anxiety, cognitions, ADHD, and comorbid indications.
PCT/IB2006/002364 2005-08-31 2006-08-21 Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions WO2007026219A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71295405P 2005-08-31 2005-08-31
US60/712,954 2005-08-31

Publications (2)

Publication Number Publication Date
WO2007026219A2 WO2007026219A2 (en) 2007-03-08
WO2007026219A3 true WO2007026219A3 (en) 2007-05-03

Family

ID=37696139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002364 WO2007026219A2 (en) 2005-08-31 2006-08-21 Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions

Country Status (4)

Country Link
JP (1) JP2007063277A (en)
AR (1) AR056192A1 (en)
TW (1) TW200800262A (en)
WO (1) WO2007026219A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106061964A (en) * 2014-01-20 2016-10-26 豪夫迈·罗氏有限公司 N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009141168A (en) * 2007-04-09 2011-05-20 Сепракор Инк. (Us) METHODS AND COMPOSITIONS CONTAINING DESENLAFAXIN OR DULOXETINE FOR THE TREATMENT OF RESPIRATORY DYSFUNCTIONS DURING SLEEP
EP2341912B1 (en) 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
ES2950875T3 (en) 2012-02-08 2023-10-16 Supernus Pharmaceuticals Inc Viloxazine Modified Release Formulations
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036867A1 (en) * 1996-03-29 1997-10-09 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors
WO1998014433A1 (en) * 1996-09-30 1998-04-09 Pfizer Inc. Aralkyl and aralkylidene heterocyclic lactams and imides
WO2005090300A1 (en) * 2004-03-17 2005-09-29 Pfizer Products Inc. Novel benzyl(idene)-lactam derivatives
WO2006136945A1 (en) * 2005-06-17 2006-12-28 Pfizer Products Inc. METABOLITES OF 1_ [_6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL] -3- [2- (4-METHYL-PIPERAZIN-I-YL) -BE NZYL] -PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036867A1 (en) * 1996-03-29 1997-10-09 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors
WO1998014433A1 (en) * 1996-09-30 1998-04-09 Pfizer Inc. Aralkyl and aralkylidene heterocyclic lactams and imides
US6380186B1 (en) * 1996-09-30 2002-04-30 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
WO2005090300A1 (en) * 2004-03-17 2005-09-29 Pfizer Products Inc. Novel benzyl(idene)-lactam derivatives
WO2006136945A1 (en) * 2005-06-17 2006-12-28 Pfizer Products Inc. METABOLITES OF 1_ [_6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL] -3- [2- (4-METHYL-PIPERAZIN-I-YL) -BE NZYL] -PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARTIGAS F: "SELECTIVE SEROTONIN/NORADRENALINE REUPTAKE INHIBITORS (SNRIS) PHARMACOLOGY AND THERAPEUTIC POTENTIAL IN THE TREATMENT OF DEPRESSIVE DISORDERS", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 4, no. 2, 1995, pages 79 - 89, XP000604093, ISSN: 1172-7047 *
BRUNELLO N ET AL: "RATIONALE FOR THE DEVELOPMENT OF NORADRENALINE REUPTAKE INHIBITORS", HUMAN PSYCHOPHARMACOLOGY. CLINICAL AND EXPERIMENTAL, JOHN WILEY & SONS LTD, vol. 13, February 1998 (1998-02-01), pages S13 - S18, XP000989785, ISSN: 0885-6222 *
DAWSON L A ET AL: "Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: Augmentation via 5-HT1A receptor antagonism", NEUROPHARMACOLOGY, vol. 38, no. 8, August 1999 (1999-08-01), pages 1153 - 1163, XP002419333, ISSN: 0028-3908 *
HALAZY S ET AL: "CENTRAL & PERIPHERAL NERVOUS SYSTEMS 5-HT1B/1D ANTAGONISTS AND DEPRESSION", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 7, no. 4, 1997, pages 339 - 352, XP001061649, ISSN: 1354-3776 *
TATARCZYNSKA EWA ET AL: "Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 487, no. 1-3, 8 March 2004 (2004-03-08), pages 133 - 142, XP002419332, ISSN: 0014-2999 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106061964A (en) * 2014-01-20 2016-10-26 豪夫迈·罗氏有限公司 N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders
CN106061964B (en) * 2014-01-20 2019-10-25 豪夫迈·罗氏有限公司 Neurogenetic N- phenyl-lactam derivatives and its purposes in the treatment of neuropathic conditions can be stimulated

Also Published As

Publication number Publication date
AR056192A1 (en) 2007-09-26
TW200800262A (en) 2008-01-01
WO2007026219A2 (en) 2007-03-08
JP2007063277A (en) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2010044981A3 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
PL2054411T3 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
IS8212A (en) New 8-aza-bicyclo [3.2.1] octane derivatives and their uses as monoamine neurotransmitter reuptake inhibitors
IL186090A0 (en) Cgrp antagonists, method for the production thereof, and their use as medicaments
WO2007019439A3 (en) Block copolymer compositions and uses thereof
WO2004047830A3 (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
ZA200705879B (en) CGRP antagonists, method for production thereof, and their use as medicaments
EP2151461A3 (en) Benzylated polyalkylene polyamines and uses thereof
EP1861357A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2007081857A3 (en) Cycloalkylamines as monoamine reuptake inhibitors
ZA200800431B (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
HK1120442A1 (en) Novel opioid antagonists
WO2007026219A3 (en) Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
IL179371A0 (en) 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
ATE477296T1 (en) CONTAINER AND COMPOSITION FOR IMPROVED GAS BARRIER PROPERTIES
TW200800967A (en) Benzimidazole thiophene compounds
WO2007122581A3 (en) Compositions and kits of phenylephrine
IL189497A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
WO2004112786A3 (en) Gaboxadol for treating depression and other affective disorders
EP2238105A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2009156680A3 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
IL182738A0 (en) Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
WO2004052858A3 (en) Inhibitors of monoamine uptake
PL2168584T3 (en) Pharmaceutical composition comprising the combination of a triazolobenzodiazepine and a selective serotonin reuptake inhibitor
ECSP066938A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A MIRTAZAPINE SALT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06795369

Country of ref document: EP

Kind code of ref document: A2